{"prompt": "['Product: MK-3475', '40', 'Protocol/Amendment No.: 604-09', 'During Cycles 1 through 4 of pembrolizumab + EP or placebo + EP:', 'If etoposide dosing is delayed or interrupted, the platinum agent and pembrolizumab', 'or saline placebo should also be delayed/interrupted. If EP is delayed or interrupted', 'during Cycles 1 through 4, patients should be seen weekly until toxicity resolves.', 'If cisplatin/carboplatin dosing is delayed or interrupted, etoposide and pembrolizumab or', 'saline placebo should also be delayed/interrupted. If EP is delayed or interrupted during', 'Cycles 1 through 4, patients should be seen weekly until toxicity resolves.', 'If pembrolizumab or saline placebo dosing is delayed or interrupted, EP therapy can', 'continue as scheduled. Pembrolizumab or saline placebo administration should be', 'attempted at the next cycle of therapy.', 'Each chemotherapy cycle may not be delayed by more than 3 weeks (>21 consecutive', 'days) despite supportive treatment. If only one of the agents is thought to be causing', 'the specified toxicity leading to a 21-day delay of administration of the next cycle,', 'that chemotherapeutic agent can be stopped and treatment can continue with', 'pembrolizumab or saline placebo and the remaining chemotherapy drug.', 'Pembrolizumab/placebd dosing can continue with 1 agent or as monotherapy.', 'The NCI CTCAE 4.0 must be used to grade the severity of AEs. All dose modifications', 'should be based on the AE requiring the greatest dose modification. Dose modifications are', 'detailed in Table 3 through Table 7.', 'Table 3', 'Dose Modifications for Study Drugs', 'Pembrolizumab/', 'Etoposide', 'Cisplatin', 'Carboplatin', 'Placebo', 'Dose Level 0', '100mg/m\u00b2/day', '75mg/m\u00b2', 'AUC 5', '200 mg', '(starting dose)', 'fixed dose', 'Dose reduction not', 'Dose Level - -1', '75mg/m\u00b2/day', '56mg/m\u00b2', 'AUC 4', 'permitted', 'Dose reduction not', 'Dose Level -2', '50mg/m\u00b2/day', '38mg/m\u00b2', 'AUC 3', 'permitted', 'Dose reduction not', 'Dose Level -3', 'Discontinue', 'Discontinue', 'Discontinue', 'permitted', '5.2.1.2.1 Pembrolizumab', 'Adverse events (both non-serious and serious) associated with pembrolizumab exposure may', 'have an immunologic etiology. These immune-related AEs (irAEs) may occur shortly after', 'the first dose or several months after the last dose of treatment and may affect more than one', 'body system simultaneously. Therefore, early recognition and initiation of treatment is', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '41', 'Protocol/Amendment No.: 604-09', 'critical to reduce complications. Based on existing clinical trial data, most irAEs were', 'reversible and could be managed with interruptions of pembrolizumab, administration of', 'corticosteroids, and/or other supportive care. For suspected irAEs, ensure adequate', 'evaluation to confirm etiology or exclude other causes. Additional procedures or tests such as', 'bronchoscopy, endoscopy, or skin biopsy may be included as part of the evaluation. Based on', 'the severity of the irAE, withhold or permanently discontinue pembrolizumab and administer', 'corticosteroids. Dose modification and toxicity management guidelines for irAEs associated', 'with pembrolizumab are provided in Table 4.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}